Abstract: Compositions and methods for treating a viral infection may comprise use of a nanoparticle composition. A nanoparticle composition of the present disclosure may comprise a targeting moiety and/or anti-viral agent and reduces the infectivity of a virus for a host cell. A method of treating a viral infection may comprise administering a composition comprising a nanoparticle of the present disclosure, to a subject and reducing the infectivity of the virus for a host cell of the subject. The compositions may be administered via intranasal or systemic administration to treat or prevent a viral infection, for example a coronavirus infection.

Abstract: A method of treating cervical cancer in a patient in need is described that includes implanting a fast release implant containing an effective amount of Cis-Pt within a cervical cancer lesion. The implant includes a polymer and a therapeutic load homogenously distributed throughout the polymer. The implant assumes a solid phase at room temperature and assumes a liquid phase at a body temperature of the patient.

Abstract: Compositions and methods of treatment for multiple myeloma (MM) are disclosed that include a liposome with a lipid bilayer shell enclosing a fluid-filled center, a targeting moiety coupled to the outer surface of the shell, a treatment compound disposed within the lipid bilayer shell or within the fluid-filled center, and an efficacy-enhancing compound disposed within the lipid bilayer shell or within the fluid-filled center. In some embodiments, the targeting moiety is PSGL-1, the proteasome-inhibiting compound is bortezomib, and the BMME-disrupting agent is a CXCR4 inhibitor or ROCK inhibitor.

Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for targeted treatment and imaging of cancers or tumors.

Abstract: The present disclosure discloses compositions, and methods of making and using nanoparticles to treat cancer. Among the various aspects of the present disclosure is the provision of a nanoparticle composition and methods of using same. For example, the nanoparticle composition can comprise a nanoparticle and antibodies conjugated to the nanoparticle surface, an antibody can recognize an epitope on cancer cells (e.g., multiple myeloma), and another antibody can engage T cells.

Abstract: Radioactive hydrogels for the delivery of localized radiotherapy, methods of making the radioactive hydrogels, and methods of using the radioactive hydrogels are disclosed. A radioisotope may be conjugated to a high molecular weight molecule, which may be encapsulated in a microparticle, where the microparticle is then dispersed within a hydrogel. The radioactive hydrogel may prevent leakage of the radioisotope to provide radiotherapy to a surgical margin while minimizing damage to surrounding normal tissue.

Abstract: A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.

Abstract: The present disclosure discloses compositions, and methods of making and using nanoparticles to treat multiple myeloma.

Abstract: A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.

Abstract: Radioactive hydrogels for the delivery of localized radiotherapy, methods of making the radioactive hydrogels, and methods of using the radioactive hydrogels are disclosed. A radioisotope may be conjugated to a high molecular weight molecule, which may be encapsulated in a microparticle, where the microparticle is then dispersed within a hydrogel. The radioactive hydrogel may prevent leakage of the radioisotope to provide radiotherapy to a surgical margin while minimizing damage to surrounding normal tissue.

Abstract: A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.

Abstract: The present disclosure is directed to a molecular signature useful in the identification multiple myeloma cells. The molecular signature advantageously identifies multiple myeloma cells under both normoxic and hypoxic conditions. The disclosed molecular signature may be used to diagnose, prognose and monitor multiple myeloma.

Abstract: A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.

Abstract: The invention relates to a device and a system for in-vivo detection of a biomarker in the gastrointestinal tract. The invention further relates to a method for the in-vivo detection of a biomarker in the gastrointestinal tract such as e.g., the ?1-antitrypsin precursor (A1AT biomarker), by using the recognition factor, e.g., trypsin immobilized to a solid surface. The invention further relates to a kit for the in-vivo detection of a biomarker in the gastrointestinal system.

Abstract: A device for in-vivo detection comprises a housing having an optical window and enclosing an imager that is configured to image the optical window. An external surface of the optical window has trypsin immobilized thereon, and may also be coated with a steric barrier protection, which may be polyethylene glycol (PEG). A trypsin-Alpha-1-antitrypsin complex formed on the window may have an affinity to a binding agent, which is tagged by a tag selected from a group consisting of a colorant, a fluorescent moiety, and a radioactive moiety.

Abstract: The present invention discloses composites which generally comprise a polymeric matrix and a hydrophobic organic compound which is associated with a radioisotope.